Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 iBio to License Green Vax Technology to G-Con | Contract Pharma

What are you searching for?

Sign in
Breaking News

iBio to License Green Vax Technology to G-Con

iBio, Inc. has agreed to license its iBioLaunch technology platform and provide technology transfer services to G-Con, LLC for the development and manufacture of plant-expressed influenza vaccines at a new facility in Bryan, TX.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

iBio, Inc. has agreed to license its iBioLaunch technology platform and provide technology transfer services to G-Con, LLC for the development and manufacture of plant-expressed influenza vaccines at a new facility in Bryan, TX. The “GreenVax Project” will show proof of concept for a large-scale vaccine production facility using Nicotiana plants grown hydroponically in a contained environment. According to iBio, its green plant technology platform has the potential to shorten vaccine production from months to weeks, allowing rapid response to newly emerging viruses not possible with conventional vaccine technology. Although the project’s initial goal is to produce candidate H1N1 vaccines, iBio’s technology is adaptable to other flu strains, infectious diseases, and cancer.

“The flexibility of the plant-based system, combined with its low cost and ability to massively scale, may provide vaccine protection not only to citizens of the U.S., but also to many parts of the world that cannot currently afford vaccines,” said Dr. Barry Holtz, president of G-Con.

“We expect vaccines against influenza, including seasonal influenza, to be among the earliest applications of the iBioLaunch technology,” said Robert Kay, chairman and chief executive officer of iBio. “In the new GreenVax facility, G-Con’s modular production technology should significantly enhance the economy, speed and flexibility advantages of our system for application to a broad range of biologic products.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters